Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 780 | 112 | 654 |
| Samples | 288 | 48 | 237 |
| Peptides | 264 | 41 | 234 |
Function
CLEC4M · C-type lectin domain family 4 member M
This gene encodes a C-type lectin that functions in cell adhesion and pathogen recognition. This receptor recognizes a wide range of evolutionarily divergent pathogens with a large impact on public health, including tuberculosis mycobacteria, and viruses including Ebola, hepatitis C, HIV-1, influenza A, West Nile virus and the SARS-CoV acute respiratory syndrome coronavirus. The protein is organized into four distinct domains: a C-terminal carbohydrate recognition domain, a flexible tandem-repeat neck domain of variable length, a transmembrane region and an N-terminal cytoplasmic domain involved in internalization. This gene is closely related in terms of both sequence and function to a neighboring gene, CD209 (Gene ID: 30835), also known as DC-SIGN. The two genes differ in viral recognition and expression patterns, with this gene showing high expression in endothelial cells of the liver, lymph node and placenta. Polymorphisms in the tandem repeat neck domain are associated with resistance to SARS infection. [provided by RefSeq, May 2020].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000327325 | Q9H2X3 | 400 | 212 |
| ENST00000596363 | Q9H2X3-9 | 302 | 145 |
| ENST00000359059 | A0A7P0MMK7* | 39 | 24 |
| ENST00000394122 | E7ENS9* | 39 | 13 |
Gene Properties
Recurrent Mutations
All 229 amino-acid changes on canonical ENST00000327325 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CLEC4M · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CLEC4M – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Melanoma | 1/210 0% | 40/1899 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 17/1390 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 9/810 1% |
| Gastric Carcinoma | 3/74 4% | 21/1809 1% |
| Endometrial Carcinoma | 0/42 0% | 8/612 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Bladder Carcinoma | 2/58 3% | 9/956 1% |
| Other Solid Cancers | 4/94 4% | 11/1515 1% |
| Colorectal Carcinoma | 3/143 2% | 28/3239 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 13/1592 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 5/752 1% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Hepatocellular Carcinoma | 2/46 4% | 8/2210 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 8/2550 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Other Blood Cancers | 2/61 3% | 5/2725 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Head and Neck Carcinoma | 1/85 1% | 3/1574 0% |
| Neuroblastoma | 0/87 0% | 3/1331 0% |
| Breast Carcinoma | 0/144 0% | 7/3264 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 3/2640 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
Mutation Distribution
Where CLEC4M is mutated · all tissues, split by cell line vs tissue
How many mutations in CLEC4M were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 40 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 780 mutations in CLEC4M
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|